Genes, Genetics, and Environment in Type 2 Diabetes: Implication in Personalized Medicine

被引:52
|
作者
Kaul, Nabodita [1 ]
Ali, Sher [1 ]
机构
[1] Natl Inst Immunol, Mol Genet Lab, New Delhi 110067, India
关键词
GENOME-WIDE ASSOCIATION; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; FASTING GLUCOSE; BIRTH-WEIGHT; LIFE-STYLE; POLYMORPHISMS; MELLITUS; RISK; VARIANTS;
D O I
10.1089/dna.2015.2883
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Type 2 diabetes (T2D) is a multifactorial anomaly involving 57 genes located on 16 different chromosomes and 136 single nucleotide polymorphisms (SNPs). Ten genes are located on chromosome 1, followed by seven genes on chromosome 11 and six genes on chromosomes 3. Remaining chromosomes harbor two to five genes. Significantly, chromosomes 13, 14, 16, 18, 21, 22, X, and Y do not have any associated diabetogenic gene. Genetic components have their own pathways encompassing insulin secretion, resistance, signaling, and -cell dysfunction. Environmental factors include epigenetic changes, nutrition, intrauterine surroundings, and obesity. In addition, ethnicity plays a role in conferring susceptibility to T2D. This scenario poses a challenge toward the development of biomarker for quick disease diagnosis or for generating a consensus to delineate different categories of T2D patients. We believe, before prescribing a generic drug, detailed genotypic information with the background of ethnicity and environmental factors may be taken into consideration. This nonconventional approach is envisaged to be more robust in the context of personalized medicine and perhaps would cause lot less burden on the patient ensuring better management of T2D.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Genetics, genomics and personalized medicine in Type 2 diabetes: a perspective on the Arab region
    Siddiqui, Khalid
    Tyagi, Shivani
    PERSONALIZED MEDICINE, 2015, 12 (04) : 417 - 431
  • [2] Personalized medicine of type 2 diabetes
    Weiping Jia
    Frontiers of Medicine, 2013, 7 : 1 - 3
  • [3] Personalized medicine of type 2 diabetes
    Jia, Weiping
    FRONTIERS OF MEDICINE, 2013, 7 (01) : 1 - 3
  • [4] Personalized medicine in Type 2 Diabetes
    Liao, Wen-Ling
    Tsai, Fuu-Jen
    BIOMEDICINE-TAIWAN, 2014, 4 (02): : 1 - 8
  • [5] Genes, the environment and personalized medicine
    Carlsten, Chris
    Brauer, Michael
    Brinkman, Fiona
    Brook, Jeffrey
    Daley, Denise
    McNagny, Kelly
    Pui, Mandy
    Royce, Diana
    Takaro, Tim
    Denburg, Judah
    EMBO REPORTS, 2014, 15 (07) : 736 - 739
  • [6] Sulfonylurea: Personalized Medicine for Type 2 Diabetes
    Hwang, You-Cheol
    ENDOCRINOLOGY AND METABOLISM, 2015, 30 (04) : 467 - 468
  • [7] Evolving to Personalized Medicine for Type 2 Diabetes
    Reddy, S. Sethu K.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2016, 45 (04) : 1011 - +
  • [8] Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care
    Pillon, Nicolas J.
    Loos, Ruth J. F.
    Marshall, Sally M.
    Zierath, Juleen R.
    CELL, 2021, 184 (06) : 1530 - 1544
  • [9] Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
    Sousa, Madalena
    Bruges-Armas, Jacome
    CURRENT DIABETES REVIEWS, 2020, 16 (08) : 807 - 819
  • [10] Proteomics for personalized medicine in type 2 diabetes mellitus
    Wang, Mark
    Gui, Yuan
    Zhou, Dong
    FASEB JOURNAL, 2021, 35